Impact of cluster of differentiation 20 expression and rituximab therapy in classical Hodgkin lymphoma: Real world experience [0.03%]
CD20表达和利妥昔单抗治疗在经典型霍奇金淋巴瘤中的影响：真实世界的经验研究
Khadega A Abuelgasim,Raed Al Shammari,Saeed Alshieban et al.
Khadega A Abuelgasim et al.
The prognostic impact of CD20 expression and rituximab therapy in classical Hodgkin lymphoma (cHL) is unclear. Among 310 patients, CD20 was expressed in 66 (22%) cases. The 3-year PFS was 75.1% for CD20+and 70% for CD20- (p = 0.36). The 3-y...
Primary peritoneal myeloid sarcoma in association with CBFB/MYH11 fusion [0.03%]
CBFB/MYH11融合基因相关的一次原发性腹腔粒细胞肉瘤的病例报告
Justin J Kuhlman,Zaid H Abdel Rahman,Liuyan Jiang et al.
Justin J Kuhlman et al.
Myeloid sarcoma, also known as chloroma or granulocytic sarcoma is an extramedullary disease process that typically presents in association with acute myeloid leukemia during initial presentation or at relapse. Often associated with cytogen...
Concurrent chronic lymphocytic leukemia and COVID-19: A comprehensive review of epidemiological, diagnostic, and therapeutic challenges [0.03%]
慢性淋巴细胞白血病与COVID-19并存：流行病学、诊断和治疗挑战的全面综述
Yousef Roosta,Farhad Behzadi,Elham Askari et al.
Yousef Roosta et al.
A comprehensive review of the literature on chronic lymphocytic leukemia (CLL) patients and recommendations regarding the evaluation and treatment of these patients was conducted. The overall prevalence of CLL and COVID-19 concurrence was f...
De-novo acute myeloid leukemia in a BRCA positive female with locally treated ductal carcinoma In Situ [0.03%]
BRCA阳性女性局部治疗导管原位癌后新发急性髓系白血病
Edward Nabrinsky,Faisal Masood,Sufyan AbdulMujeeb et al.
Edward Nabrinsky et al.
Acute myeloid leukemia (AML) is primarily a disease of older adults and can arise de novo, in relation to previous treatment or in the setting of underlying hematological disease. While it is known to arise from chemoradiation in the settin...
Auer rods in mixed phenotype acute leukemia, T/myeloid: A report of three cases [0.03%]
混合表型急性白血病-T/髓样中的奥尔小体-三例报告
Yan Li,Wenrui Yang,Wei Wang et al.
Yan Li et al.
Fludarabine-based salvage therapy for refractory/relapsed acute leukemias: A single center experience [0.03%]
氟达拉滨为基础的挽救疗法治疗难治和复发急性白血病：单中心经验报告
Abdul Muqtadir Abbasi,Usman Shaikh,Natasha Ali et al.
Abdul Muqtadir Abbasi et al.
Hematogones in patients with acute myeloid leukaemia: Prognostic value and correlation with minimal residual disease [0.03%]
急性髓系白血病患者中的造血祖细胞：预后价值及其与微小残留病灶的相关性研究
Rita Tavarozzi,Enrica Manzato,Riccardo Morganti et al.
Rita Tavarozzi et al.
Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1 [0.03%]
ABL酪氨酸激酶抑制剂成功治疗携带BCR-ABL1基因的急性髓系白血病患者
Asako Takeuchi,Toshinori Kondo,Taizo Tasaka et al.
Asako Takeuchi et al.
Acute myeloid leukemia (AML) with BCR-ABL1 is rare and has a poor prognosis with conventional chemotherapy or ABL tyrosine kinase inhibitors (TKIs) alone. We reported a case of AML with BCR-ABL1 patient who was successfully treated with das...
Prognostic impact of peripheral blood Wilms' tumour 1 mRNA expression levels in response to azacytidine in MDS: A single-centre analysis [0.03%]
地西他滨反应中MDS患者外周血WT1基因表达的预后价值：单中心分析
Tomoya Maeda,Akira Matsuda,Chie Asou et al.
Tomoya Maeda et al.
To determine the impact of peripheral blood (PB) Wilms' tumour 1 (WT-1) mRNA levels in patients with primary myelodysplastic syndromes (MDS), we analysed the relationships between several clinical variables at the time of diagnosis and the ...
Acute aleukemic mast cell leukemia: Report of a case and review of the literature [0.03%]
急性无粒细胞型mast细胞白血病一例报告及文献复习
Gian M Galura,Sundar V Cherukuri,Nawar Hakim et al.
Gian M Galura et al.
Mast Cell Leukemia (MCL) is the rarest form of systemic mastocytosis, a rare group of neoplastic disease that result from clonal proliferation of mast cells and their accumulation in one or more organ systems. The diagnosis of MCL is made b...